(Q40912350)

24 September 2017

1 reference

title

Lipoprotein metabolism and renal failure (English)

1 reference

24 September 2017

Attman PO

1

1 reference

24 September 2017

Samuelsson O

series ordinal

2

1 reference

24 September 2017

Alaupovic P

series ordinal

3

1 reference

24 September 2017

publication date

1 June 1993

1 reference

American Journal of Kidney Diseases

24 September 2017

published in

1 reference

24 September 2017

volume

21

1 reference

24 September 2017

issue

6

1 reference

24 September 2017

page(s)

573-592

1 reference

Lipid abnormalities in renal disease

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipid abnormalities in uremia, dialysis, and transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

The uremic dyslipoproteinemia: its characteristics and relations to clinical factors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hyperlipidaemia and renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hyperlipoproteinemia in chronic renal failure: pathophysiological and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipid and apolipoprotein profiles of uremic dyslipoproteinemia--relation to renal function and dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipoproteins and apolipoproteins during the progression of chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hypertriglyceridemia in patients with chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Further definition of lipid-lipoprotein abnormalities in children with various degrees of chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipid and carbohydrate metabolism in uraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: a comparison with type IV hyperlipoproteinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

The influence of continuous ambulatory peritoneal dialysis on plasma lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Prevalence of serum lipid abnormalities in chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

A longitudinal study of lipid abnormalities in renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Serum lipids and lipoproteins during continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Effects of Long-Term Haemodialysis on Lipid, Lipoprotein and Apolipoprotein Levels of Black Patients with Chronic Renal Failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipoprotein metabolism and the role of apolipoproteins as metabolic programmers

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein genetic variation and human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein composition as the basis for classifying plasma lipoproteins. Characterization of ApoA- and ApoB-containing lipoprotein families

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein E: cholesterol transport protein with expanding role in cell biology

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Regulation of plasma cholesterol by lipoprotein receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Functional activities of hepatic lipoprotein receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Serum apolipoprotein profile of patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hypertriglyceridemia. A metabolic consequence of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apoprotein A-I and high density lipoprotein subfractions in patients with chronic renal failure receiving hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Selective Deficiency of Hepatic Triglyceride Lipase in Uremic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein and lipid abnormalities in uremic children on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Sequential changes in serum lipids and their subfractions in patients receiving continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Decreased VLDL apoprotein CII/apoprotein CIII ratio may be seen in both normotriglyceridemic and hypertriglyceridemic patients on chronic hemodialysis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Anomalies in composition of uremic lipoproteins isolated by gradient ultracentrifugation: relative enrichment of HDL in apolipoprotein C-III at the expense of apolipoprotein A-I

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Quantitative and qualitative changes of apolipoprotein AI-containing lipoproteins in patients on continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Changes in lipoproteins induced by the remnant kidney tissue or binephrectomy in chronic uremic patients treated by hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

High-density lipoprotein cholesterol subfractions in chronic uremia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Comparison of lipids, apoproteins and associated enzyme activities between diabetic and nondiabetic end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Impaired metabolism of high density lipoprotein in uremic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Dyslipoproteinemia in diabetic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein B-containing lipoprotein particles in progressive renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Abnormalities of lipoprotein composition in renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Accumulation of lipoprotein remnants in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Increased lipoprotein-remnant formation in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Increased frequency of late pre- beta lipoproteins (LP beta) in isolated serum very low density lipoproteins in uraemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Fat transport in lipoproteins--an integrated approach to mechanisms and disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Heterogeneity of very-low-density lipoprotein metabolism in hyperlipidemic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Metabolic heterogeneity in very low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Kinetics of LDL subfractions

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Separation of ApoA- and ApoB-containing lipoproteins of human plasma by affinity chromatography on concanavalin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Separation and identification of apo-B-containing lipoprotein particles in normolipidemic subjects and patients with hyperlipoproteinemias.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein A-I containing lipoproteins in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Evaluation of apolipoprotein A-I containing particles in chronic renal failure patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipoprotein (a). Heterogeneity and biological relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipid and lipoprotein (a) concentrations in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Defective triglyceride removal in lipemia associated with peritoneal dialysis and haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Reduction of plasma triglycerides by diet in subjects with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hyperlipoproteinemia in experimental chronic renal insufficiency in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Impaired plasma triglyceride clearance as a feature of both uremic and posttransplant triglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Factors of increase in serum triglyceride-rich lipoproteins in uremic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Retinyl ester retention in chronic renal failure. Further evidence for a defect in chylomicron remnant metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Inhibition of lipoprotein lipase by uremic plasma, a possible cause of hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Postheparin plasma triglyceride lipases in chronic hemodialysis: Evidence for a role for hepatic lipase in lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Increase in Lipoprotein Lipase during Clofibrate Treatment of Hypertriglyceridemia in Patients on Hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Effect of protein-reduced diet on plasma lipids, apolipoproteins and lipolytic activities in patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Plasma lipoproteins and lecithin:cholesterol acyltransferase distribution in patients on dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Roles of hypoalbuminemia and lipoprotein lipase on hyperlipoproteinemia in continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Glucose and insulin metabolism in uremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Treatment of uremic hypertriglyceridaemia with bezafibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Early changes of plasma lipid status and glucose tolerance during the course of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Abnormal cell-interactive properties of low-density lipoproteins isolated from patients with chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Increased Lipid Peroxidation in Patients on Maintenance Hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

The effect of renal failure and haemodialysis on the concentration of free apolipoprotein A-1 in serum and the implications for the catabolism of high-density lipoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein E synthesis in human kidney, adrenal gland, and liver

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Chronic renal failure: pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Blood lipid profile in hemodialysis patients treated with human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Accelerated atherosclerosis in prolonged maintenance hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Arterial calcification and pathology in uremic patients undergoing dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

The role of hypertension in hemodialysis-associated atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Relationship of coronary risk factors to hemodialysis-associated ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

CHD risk factors: a Framingham study update

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Update on the pathogenesis of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Cardiovascular risk factors in chronic renal failure and hemodialysis populations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Management of hyperlipidemia of kidney disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Blood lipids, lipid-related measures, and the risk of atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

The status of hypertriglyceridemia as a risk factor for coronary heart disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Plasma triglyceride and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hypertriglyceridaemia, triglyceride-rich lipoproteins and coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

A fresh look at the atherogenic remnant hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

The progression of renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Hypertension and renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipids in the progression of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Apolipoprotein-B-containing lipoproteins and the progression of renal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipids and progressive glomerulosclerosis. A model analogous to atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Possible association between an abnormal low density lipoprotein and nephropathy in lecithin: cholesterol acyltransferase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Renal lipidoses: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Abnormal lipoprotein and apolipoprotein pattern in lipoprotein glomerulopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Significance of renal hyaline arteriolosclerosis in focal segmental glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lipids and the kidney

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Cholestyramine resin ameliorates chronic aminonucleoside nephrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Effects of fish oil rich in eicosapentaenoic acid on serum lipid in hyperlipidemic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Multicenter trial of L-carnitine in maintenance hemodialysis patients. I. Carnitine concentrations and lipid effects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980030-8

7 January 2021

10.1016/S0272-6386(12)80030-8

Identifiers

DOI

1 reference

24 September 2017

1 reference